glp 1 agonists for obesity used weight loss GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight GLP-1 Receptor Agonist Market Growth

Studies show that up to 40% of weight lost on GLP-1 medications can be lean muscle massnot just fat

Acute pancreatitis has been reported, though causality remains debated

This summary highlights key developments in adherence, dosing, innovation, mental health, and access that are shaping clinical practice and patient outcomes

In addition, it is important to schedule regular follow-ups so that all outcomes can be meticulously tracked

It's crucial to understand the diverse side-effect profiles associated with these medications

In this respect, the dual agonist effect of tirzepatide seems to give it a superiority on semaglutide, with a greater decrease (more than 2%) in glycated hemoglobin (A1c), a marker of chronic hyperglycemia (Figure 4)